|
REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
|
1R01CA193321-01
|
$362,569
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-09
|
$3,155,163
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S2
|
$112,151
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-09S3
|
$183,048
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
TARGETING INOS TO INHIBIT MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) IN MELANOMA
|
5K08CA154963-05
|
$134,865
|
SIKORA, ANDREW
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
|
5R01CA148748-05
|
$325,652
|
SONG, XIAO-TONG
|
BAYLOR COLLEGE OF MEDICINE
|
|
CpG-ODN Coated Hollow Gold Nanoshells for Photothermal Therapy
|
5R01CA172836-03
|
$342,894
|
FOSTER, AARON
|
BELLICUM PHARMACEUTICALS, INC.
|
|
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)
|
5R01CA170158-04
|
$361,050
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Why red-haired individuals are so prone to developing melanoma
|
1R01CA196896-01
|
$374,464
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-29S2
|
$334,740
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
|
5R01CA173610-03
|
$361,144
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Psoralens and melanoma
|
1R21CA198216-01
|
$221,938
|
CHO, EUNYOUNG
|
BROWN UNIVERSITY
|
|
Nanosystems Biology Cancer Center
|
1U54CA199090-01
|
$2,324,988
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
|
5R01CA170689-04
|
$626,768
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Validation of Genomic Targets in Melanoma
|
5R01CA114337-11
|
$312,281
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
PHIP as a Biomarker of Triple-Negative Melanoma
|
5R01CA175768-02
|
$424,835
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
Targeting an MT1-MMP/MMP2 axis in melanoma by a novel MT1-MMP/MMP2 inhibitor
|
1R21CA187695-01A1
|
$217,926
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting the developmental pathways Notch and ERBB for melanoma therapy
|
5R01CA177652-02
|
$358,346
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Bone Marrow MSCs/Pericytes: Gatekeepers Controlling Skeletal Metastasis.
|
5R01CA163562-04
|
$325,775
|
CAPLAN, ARNOLD
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S1
|
$37,026
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-25S2
|
$49,999
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-25
|
$4,878,887
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-01S1
|
$171,796
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-02
|
$1,360,245
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
The Development of Novel Mechanistically-based APE/Ref-1 Redox Inhibitors
|
7K08CA179084-02
|
$114,468
|
YANG, SUN
|
CHAPMAN UNIVERSITY
|
|
Immunology of human malignant melanoma initiating cells
|
5R01CA158467-04
|
$364,127
|
FRANK, MARKUS
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Defining oncogenic capacities of PAK7 mutations in human cancer
|
1R21CA184656-01A1
|
$230,333
|
HANSEN, STEEN
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Cancer biology in the zebrafish
|
5R01CA103846-13
|
$371,851
|
ZON, LEONARD
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Improving adoptive cell therapy by enhancing T cell longevity
|
1R21CA188767-01A1
|
$206,843
|
DIAZ-MONTERO, CLAUDIA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Integrative Cancer Genomics: Drivers, Pathways and Drugs
|
5R01CA164729-04
|
$554,295
|
PE'ER, DANA
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Cancer Center Support Grant
|
3P30CA006516-50S1
|
$122,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S2
|
$50,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S3
|
$125,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S4
|
$200,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S5
|
$62,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-50
|
$11,162,542
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Overcoming resistance to targeted therapy in cancer
|
1R35CA197737-01
|
$473,472
|
GARRAWAY, LEVI
|
DANA-FARBER CANCER INST
|
|
Developing Selective EphA2 Inhibitors for the treatment of Cancer
|
5R01CA173469-03
|
$524,549
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
ECOG-ACRIN Network Group Statistics and Data Management Center
|
5U10CA180794-02
|
$6,421,209
|
GRAY, ROBERT
|
DANA-FARBER CANCER INST
|
|
Comparative Assessment of Screening Strategies for Melanoma
|
5R21CA182241-02
|
$225,765
|
LEE, SANDRA
|
DANA-FARBER CANCER INST
|
|
Analysis of cap-dependent translational repression by microRNAs in oncogensis
|
5R01CA140986-05
|
$326,813
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-02
|
$692,567
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
Metabolic Vulnerabilities in Melanoma Tumors
|
5R01CA181217-02
|
$348,087
|
PUIGSERVER, PERE
|
DANA-FARBER CANCER INST
|
|
Dartmouth Lead Participation in NCI National Clinical Trials Network
|
5U10CA180854-02
|
$319,472
|
DRAGNEV, KONSTANTIN
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
2P30CA023108-36
|
$3,139,824
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-36S1
|
$62,500
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-36S2
|
$15,000
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
3P30CA023108-36S3
|
$124,999
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Combinational Therapy of Melanoma using T Cells and site-specific Immunomodulator
|
1R03CA188418-01A1
|
$81,000
|
MULLINS, DAVID
|
DARTMOUTH COLLEGE
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-03
|
$336,150
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|